[{"id":"e8456c97-4ee4-47f4-89b8-43e1a9f2db63","acronym":"PALBONET","url":"https://clinicaltrials.gov/study/NCT02806648","created_at":"2021-01-18T13:45:55.470Z","updated_at":"2024-07-02T16:37:14.609Z","phase":"Phase 2","brief_title":"A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)","source_id_and_acronym":"NCT02806648 - PALBONET","lead_sponsor":"Grupo Espanol de Tumores Neuroendocrinos","biomarkers":" RB1 • CCND1 • CDK4 • CDK6","pipe":" | ","alterations":" CCND1 overexpression • CDK4 overexpression • RB1 overexpression • CDK6 expression","tags":["RB1 • CCND1 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression • CDK4 overexpression • RB1 overexpression • CDK6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 07/01/2017","primary_completion_date":" 07/01/2017","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2018-01-23"}]